Stock Events

Stock Events

Longeveron 

$6.59
81
-$0.22-3.23% 19:12 Today

Statistics

Day High
6.78
Day Low
6.59
52W High
11.6
52W Low
4.84
Volume
463
Avg. Volume
-
Mkt Cap
21.01M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.9
-1.33
-0.75
-0.18
Expected EPS
-1.633333
Actual EPS
N/A

Financials

-1,893.58%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.2MRevenue
-22.7MNet Income

Analyst Ratings

8.00Average Price Target
The highest estimate is 8.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LGVN. It's not an investment recommendation.
NVIDIA
18
NVDA
Apple
13
AAPL
Amazon
13
AMZN
Palantir Technologies
11
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap2.25B
Mesoblast Limited focuses on the development of regenerative medicine, which competes directly with Longeveron's stem cell therapy products.
Biolife Solutions
BLFS
Mkt Cap1.72B
BioLife Solutions, Inc. provides bioproduction tools and services, including cell and gene therapy solutions, indirectly competing with Longeveron by supporting the broader regenerative medicine industry.
CRISPR Therapeutics
CRSP
Mkt Cap5.39B
CRISPR Therapeutics AG focuses on gene editing technologies, which represent a competitive approach to Longeveron's regenerative treatments through potentially more targeted interventions.
Editas Medicine
EDIT
Mkt Cap496.06M
Editas Medicine, Inc. is another company working on gene editing, competing with Longeveron by offering alternative solutions to medical conditions potentially treatable by regenerative medicine.
Intellia Therapeutics
NTLA
Mkt Cap1.79B
Intellia Therapeutics, Inc. specializes in CRISPR/Cas9 gene editing, posing competition to Longeveron's cell therapy approach by targeting genetic diseases at their source.
Vericel
VCEL
Mkt Cap2.06B
Vericel Corporation produces autologous cell therapies for the treatment of patients with serious diseases and conditions, directly competing with Longeveron's therapeutic approach.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap11.92M
Brainstorm Cell Therapeutics Inc. works on developing innovative, autologous stem cell therapies for neurodegenerative diseases, competing in a similar niche as Longeveron.
Fate Therapeutics
FATE
Mkt Cap297.15M
Fate Therapeutics, Inc. is dedicated to the development of programmed cellular immunotherapies, competing with Longeveron by advancing alternative regenerative medicine and cell therapy techniques.

About

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Show more...
CEO
Stephen H. Willard
Employees
38
Country
United States
ISIN
US54303L3024

Listings

XNAS
US
LGVN
BOATS
BOATS
LGVN.BOATS

0 Comments

Share your thoughts

FAQ

What is Longeveron stock price today?▼
The current price of LGVN is $6.59 USD — it has decreased by -3.23% in the past 24 hours. Watch Longeveron stock price performance more closely on the chart.
What is Longeveron stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Longeveron stocks are traded under the ticker LGVN.
Is Longeveron stock price growing?▼
LGVN stock has fallen by -2.37% compared to the previous week, the month change is a -13.97% fall, over the last year Longeveron has showed a -22.38% decrease.
What is Longeveron market cap?▼
Today Longeveron has the market capitalization of 21.01M
When is the next Longeveron earnings date?▼
Longeveron is going to release the next earnings report on November 06, 2026.
What were Longeveron earnings last quarter?▼
LGVN earnings for the last quarter are -1.9 USD per share, whereas the estimation was -1.75 USD resulting in a -8.57% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Longeveron revenue for the last year?▼
Longeveron revenue for the last year amounts to 1.2M USD.
What is Longeveron net income for the last year?▼
LGVN net income for the last year is -22.7M USD.
How many employees does Longeveron have?▼
As of September 08, 2026, the company has 38 employees.
In which sector is Longeveron located?▼
Longeveron operates in the Health & Wellness sector.
When did Longeveron complete a stock split?▼
The last stock split for Longeveron was on August 27, 2026 with a ratio of 1:10.
Where is Longeveron headquartered?▼
Longeveron is headquartered in MIAMI, United States.